These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

537 related items for PubMed ID: 29115905

  • 1. Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea.
    Zhang XH, Leeuwenkamp O, Oh KB, Lee YE, Kim CM.
    Hum Vaccin Immunother; 2018 Jan 02; 14(1):85-94. PubMed ID: 29115905
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model.
    Delgleize E, Leeuwenkamp O, Theodorou E, Van de Velde N.
    BMJ Open; 2016 Nov 30; 6(11):e010776. PubMed ID: 27903558
    [Abstract] [Full Text] [Related]

  • 3. Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model.
    De Wals P, Black S, Borrow R, Pearce D.
    Clin Ther; 2009 Oct 30; 31(10):2152-69. PubMed ID: 19922887
    [Abstract] [Full Text] [Related]

  • 4. Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy.
    Castiglia P, Pradelli L, Castagna S, Freguglia V, Palù G, Esposito S.
    Hum Vaccin Immunother; 2017 Oct 03; 13(10):2307-2315. PubMed ID: 28700264
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru.
    Gomez JA, Tirado JC, Navarro Rojas AA, Castrejon Alba MM, Topachevskyi O.
    BMC Public Health; 2013 Oct 30; 13():1025. PubMed ID: 24171921
    [Abstract] [Full Text] [Related]

  • 7. A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand.
    Varghese L, Talbot L, Govender A, Zhang XH, Mungall BA.
    Appl Health Econ Health Policy; 2018 Jun 30; 16(3):331-345. PubMed ID: 29633160
    [Abstract] [Full Text] [Related]

  • 8. Estimated Annual Health and Cost Impact of PHiD-CV Immunization Program in Brazil.
    Gomez JA, Lopes de Abreu AJ, Caceres DC, Nieto J, Ortega-Barria E.
    Pediatr Infect Dis J; 2019 Oct 30; 38(10):e260-e265. PubMed ID: 31568144
    [Abstract] [Full Text] [Related]

  • 9. Cost-Effectiveness Comparison of Pneumococcal Conjugate Vaccines in Turkish Children.
    Marijam A, Olbrecht J, Ozakay A, Eken V, Meszaros K.
    Value Health Reg Issues; 2019 Sep 30; 19():34-44. PubMed ID: 30776766
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine for children in Taiwan.
    Lu CY, Chung CH, Huang LM, Kruger E, Tan SC, Zhang XH, Chiu NC.
    Cost Eff Resour Alloc; 2020 Sep 30; 18():30. PubMed ID: 32874139
    [Abstract] [Full Text] [Related]

  • 11. Reduced middle ear infection with non-typeable Haemophilus influenzae, but not Streptococcus pneumoniae, after transition to 10-valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine.
    Leach AJ, Wigger C, Hare K, Hampton V, Beissbarth J, Andrews R, Chatfield M, Smith-Vaughan H, Morris PS.
    BMC Pediatr; 2015 Oct 19; 15():162. PubMed ID: 26482232
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.
    Tregnaghi MW, Sáez-Llorens X, López P, Abate H, Smith E, Pósleman A, Calvo A, Wong D, Cortes-Barbosa C, Ceballos A, Tregnaghi M, Sierra A, Rodriguez M, Troitiño M, Carabajal C, Falaschi A, Leandro A, Castrejón MM, Lepetic A, Lommel P, Hausdorff WP, Borys D, Ruiz Guiñazú J, Ortega-Barría E, Yarzábal JP, Schuerman L, COMPAS Group.
    PLoS Med; 2014 Jun 19; 11(6):e1001657. PubMed ID: 24892763
    [Abstract] [Full Text] [Related]

  • 13. Economic evaluation of second generation pneumococcal conjugate vaccines in Norway.
    Robberstad B, Frostad CR, Akselsen PE, Kværner KJ, Berstad AK.
    Vaccine; 2011 Nov 03; 29(47):8564-74. PubMed ID: 21945264
    [Abstract] [Full Text] [Related]

  • 14. Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea.
    Sohn HS, Suh DC, Jang E, Kwon JW.
    J Manag Care Pharm; 2010 Nov 03; 16(1):32-45. PubMed ID: 20044845
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR, Rosen MM, Zeng W, Yap M, Pwee KH, Ang LW, Shepard DS.
    Vaccine; 2011 Sep 02; 29(38):6686-94. PubMed ID: 21745516
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model.
    Bakır M, Türel O, Topachevskyi O.
    BMC Health Serv Res; 2012 Nov 09; 12():386. PubMed ID: 23137037
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia.
    Wang XJ, Saha A, Zhang XH.
    Cost Eff Resour Alloc; 2017 Nov 09; 15():17. PubMed ID: 28852326
    [Abstract] [Full Text] [Related]

  • 18. Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise.
    Knerer G, Ismaila A, Pearce D.
    J Med Econ; 2012 Nov 09; 15(1):61-76. PubMed ID: 22026590
    [Abstract] [Full Text] [Related]

  • 19. Impact of protein D-containing pneumococcal conjugate vaccines on non-typeable Haemophilus influenzae acute otitis media and carriage.
    Clarke C, Bakaletz LO, Ruiz-Guiñazú J, Borys D, Mrkvan T.
    Expert Rev Vaccines; 2017 Jul 09; 16(7):1-14. PubMed ID: 28571504
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D-Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media-A Double-Blind Randomized Clinical Trial in Finland.
    Vesikari T, Forsten A, Seppä I, Kaijalainen T, Puumalainen T, Soininen A, Traskine M, Lommel P, Schoonbroodt S, Hezareh M, Moreira M, Borys D, Schuerman L.
    J Pediatric Infect Dis Soc; 2016 Sep 09; 5(3):237-248. PubMed ID: 27125273
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.